# HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL

> **NCT01873807** · PHASE4 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** IDA
- **RADIATION:** TBI
- **DRUG:** CTX
- **DRUG:** VP-16

## Key facts

- **NCT ID:** NCT01873807
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873807, "HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01873807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*